Latest News & Features
Europe
London’s MedCity is working to boost collaboration between businesses in the area and invigorate the UK’s so-called ‘golden triangle’ life sciences cluster, with its three major centres in London, Oxford and Cambridge. LSIPR heard from Eliot Forster, who chairs MedCity, about the initiative. 30 May 2014
Americas
With the Federal Circuit relying on the precedent set by the Prometheus and Myriad decisions, Dolly the sheep has been summarily declared ineligible for patent protection. Nabeela Rasheed sums up the implications. 30 May 2014
Europe
Horizon Discovery’s cell line-creating technology has the potential to advance personalised medicine. But how does the gene editing company stay
competitive in a crowded field? LSIPR found out. 30 April 2014
Asia
Arguments over the term of the patents granted are at the heart of the Copaxone conflict, says Archana Shanker. 30 April 2014
Americas
With careful patent drafting and prosecution, it is possible to capture significant IP value in the clinically—and commercially—important area of biomarkers, says Stephanie Pilkington of Potter Clarkson. 30 April 2014
Asia
International damage may result from India’s steps to formalise its isolationist patents regime, says Jason Rutt. 30 April 2014
Asia
Strand Life Sciences’ ‘virtual’ liver could cut the failure rate of drug development by giving researchers a clearer idea which of the potential drugs are unlikely to work. How does the Bangalore-based company protect and license its technology? 31 March 2014
Americas
Myriad has failed to stop Ambry offering genetic tests using the BRCA1 or BRCA2 genes, but Ambry raised a
substantial question about the validity of the claims of Myriad’s patents, as MaryAnne Armstrong reports. 31 March 2014
article
Many researchers are unaware of the legalities when it comes to sharing and using copyrighted material, but licensing agreements can help, says Kate Alzapiedi of copyright licensing firm RightsDirect. 31 March 2014
Europe
Recent CJEU decisions on SPCs have brought little clarity to the meaning of ‘product’, and a recent Advocate General opinion in Bayer CropScience AG threatens to muddy the waters even further, says Paul England. 28 February 2014